Astrazeneca annual stock-based compensation
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Astrazeneca Stock-Based Compensation Growth & History (AZN)
Astrazeneca's stock-based compensation was $719.0M for fiscal 2025.
View full Astrazeneca company overviewAstrazeneca annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $719.0M | $59.0M | +8.94% |
| 2024 | 2024-12-31 | $660.0M | $81.0M | +13.99% |
| 2023 | 2023-12-31 | $579.0M | −$40.0M | −6.46% |
| 2022 | 2022-12-31 | $619.0M | $4.0M | +0.65% |
| 2021 | 2021-12-31 | $615.0M | $338.0M | +122.02% |
| 2020 | 2020-12-31 | $277.0M | $18.0M | +6.95% |
| 2019 | 2019-12-31 | $259.0M | $40.0M | +18.26% |
| 2018 | 2018-12-31 | $219.0M | −$1.0M | −0.45% |
| 2017 | 2017-12-31 | $220.0M | −$21.0M | −8.71% |
| 2016 | 2016-12-31 | $241.0M | $30.0M | +14.22% |
| 2015 | 2015-12-31 | $211.0M | — | — |
Astrazeneca stock-based compensation trends
Over the last five fiscal years, Astrazeneca's stock-based compensation increased from $277.0M to $719.0M, a change of $442.0M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...